Galimedix Therapeutics earns milestone payment in ophthalmology partnership with Théa Open ...

Galimedix Therapeutics earns milestone payment in ophthalmology partnership with Théa Open ...

Kensington, MD, USA and Munich/Martinsried, Germany, March 12, 2026 (GLOBE NEWSWIRE) -- Galimedix Therapeutics earns milestone payment in ophthalmology partnership

Galimedix Achieves Milestone Payment After Phase 1 Success of GAL-101 for GA

Key Takeaways Galimedix completed a phase 1 trial of oral GAL-101, triggering an undisclosed milestone payment from Théa Open Innovation  The eye drop formulation of GAL-101 is currently being evaluated in a phase 2 trial for geographic atrophy (GA) Early clinical results showed oral GAL-101 to be safe, well tolerated, and capable of crossing the blood-brain barrier, supporting further development in Alzheimer’s disease and other indicat…